Ad
related to: mouse models of lung fibrosis treatment protocol side effects list
Search results
Results from the WOW.Com Content Network
Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) receptor agonist and is the first medication that targets PPAR-alpha, PPAR-beta, and PPAR-gamma simultaneously.
Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.
In simpler models, PCLS have been used to assess the impact of LPS on the innate immune response, testing the effects of various immunomodulators on innate signaling. [ 29 ] [ 23 ] Furthermore, the ability to obtain slices from diseased lungs, such as those affected by conditions like COPD and asthma, provides a robust model for studying how ...
Pulmonary drug delivery is mainly utilized for topical applications in the lungs, such as the use of inhaled beta-agonists, corticosteroids and anticholinergic agents for the treatment of asthma and COPD, the use of inhaled mucolytics and antibiotics for the treatment of cystic fibrosis (CT) and respiratory viral infections, [1] and the use of inhaled prostacyclin analogs for the treatment of ...
The term fibrothorax implies severe fibrosis affecting both the visceral and the outer (parietal) pleura, fusing the lung to the chest wall. [2] The condition starts as an undrained pleural effusion. Over time, the undrained pleural effusion causes sustained inflammation of the pleura, which can then lead to deposition of fibrin in the pleura ...
Pulmonary fibrosis is a condition in which the lungs become scarred over time. [1] Symptoms include shortness of breath , a dry cough, feeling tired, weight loss, and nail clubbing . [ 1 ] Complications may include pulmonary hypertension , respiratory failure , pneumothorax , and lung cancer .
Side effects on the lungs can be very varied, and can include signs and symptoms that are either clinical, or radiological (i.e., seen on chest X-ray or CT), or both.They can include lung inflammation (pneumonitis), secondary (in this context, indirectly caused) lung infection (), lung fibrosis, organising pneumonia (bronchiolitis obliterans organising pneumonia, BOOP), ARDS (acute respiratory ...
It is a type of chronic pulmonary fibrosis characterized by a progressive and irreversible decline in lung function. [6] [3] [4] The tissue in the lungs becomes thick and stiff, which affects the tissue that surrounds the air sacs in the lungs. [7] Symptoms typically include gradual onset of shortness of breath and a dry cough. [1]
Ad
related to: mouse models of lung fibrosis treatment protocol side effects list